Literature DB >> 17512240

Role of fibroblast growth factor 8 in growth and progression of hormonal cancer.

Mirjami M Mattila1, Pirkko L Härkönen.   

Abstract

Hormonal cancers such as breast and prostate cancer arise from steroid hormone-regulated tissues. In addition to breast and prostate cancer hormonal regulation has also a role in endometrial, ovarian, testis and thyroid carcinomas. The effects of estrogens, androgens and progestagens on tumor growth are largely mediated by paracrine and autocrine target molecules which include growth factors and growth factor receptors. During cancer progression the hormonal growth regulation is often lost or overcome by an inappropriate activation of growth factor signaling cascades. One of the growth factors which have been associated with the regulation of growth and progression of hormonal cancer is fibroblast growth factor 8 (FGF8) which has also been recognized as an oncogene. FGF8 is widely expressed during embryonic development. It has been shown to mediate embryonic epithelial-mesenchymal transition and to have a crucial role in gastrulation and early organization and differentiation of midbrain/hindbrain, pharyngeal, cardiac, urogenital and limb structures. During adulthood FGF8 expression is much more restricted but in hormonal cancers it becomes frequently activated. High level of FGF8 expression in tumors is associated with a poor prognosis at least in prostate cancer. In experimental models FGF8 induces and facilitates prostate tumorigenesis and increases growth and angiogenesis of tumors. Several lines of evidence for autocrine and paracrine loops in the growth regulation of breast, prostate and ovarian cancer by FGF8 have been suggested.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17512240     DOI: 10.1016/j.cytogfr.2007.04.010

Source DB:  PubMed          Journal:  Cytokine Growth Factor Rev        ISSN: 1359-6101            Impact factor:   7.638


  24 in total

Review 1.  FGF receptor inhibitors: role in cancer therapy.

Authors:  Gennaro Daniele; Jesus Corral; L Rhoda Molife; Johann S de Bono
Journal:  Curr Oncol Rep       Date:  2012-04       Impact factor: 5.075

2.  Variants in genes belonging to the fibroblast growth factor family are associated with lower extremity amputation in non-Hispanic whites: Findings from the chronic renal insufficiency cohort study.

Authors:  Jayanta Gupta; Nandita Mitra; Raymond R Townsend; Michael Fischer; Jeffrey R Schelling; David J Margolis
Journal:  Wound Repair Regen       Date:  2016-06-20       Impact factor: 3.617

3.  Targeting multiple tyrosine kinase receptors with Dovitinib blocks invasion and the interaction between tumor cells and cancer-associated fibroblasts in breast cancer.

Authors:  Chuanbing Zang; Jan Eucker; Piet Habbel; Christian Neumann; Carsten-Oliver Schulz; Nikola Bangemann; Lutz Kissner; Hanno Riess; Hongyu Liu
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

4.  Updates on the cytogenetics and molecular cytogenetics of benign and intermediate soft tissue tumors.

Authors:  Jun Nishio
Journal:  Oncol Lett       Date:  2012-10-30       Impact factor: 2.967

5.  Fast growth associated with aberrant vasculature and hypoxia in fibroblast growth factor 8b (FGF8b) over-expressing PC-3 prostate tumour xenografts.

Authors:  Johanna Tuomela; Tove J Grönroos; Maija P Valta; Jouko Sandholm; Aleksi Schrey; Jani Seppänen; Päivi Marjamäki; Sarita Forsback; Ilpo Kinnunen; Olof Solin; Heikki Minn; Pirkko L Härkönen
Journal:  BMC Cancer       Date:  2010-10-30       Impact factor: 4.430

6.  Zebrafish Hagoromo mutants up-regulate fgf8 postembryonically and develop neuroblastoma.

Authors:  Adam Amsterdam; Kevin Lai; Anna Z Komisarczuk; Thomas S Becker; Roderick T Bronson; Nancy Hopkins; Jacqueline A Lees
Journal:  Mol Cancer Res       Date:  2009-06-16       Impact factor: 5.852

7.  Cyclin E and FGF8 are downstream cell growth regulators in distinct tumor suppressor effects of ANXA7 in hormone-resistant cancer cells of breast versus prostate origin.

Authors:  A Bera; X-M Leighton; H Pollard; M Srivastava
Journal:  Trends Cancer Res       Date:  2018

8.  Differential roles of fibroblast growth factor receptors (FGFR) 1, 2 and 3 in the regulation of S115 breast cancer cell growth.

Authors:  Kati M Tarkkonen; Emeli M Nilsson; Tiina E Kähkönen; Julien H Dey; Jari E Heikkilä; Johanna M Tuomela; Qing Liu; Nancy E Hynes; Pirkko L Härkönen
Journal:  PLoS One       Date:  2012-11-21       Impact factor: 3.240

9.  PCA3 noncoding RNA is involved in the control of prostate-cancer cell survival and modulates androgen receptor signaling.

Authors:  Luciana Bueno Ferreira; Antonio Palumbo; Kivvi Duarte de Mello; Cinthya Sternberg; Mauricio S Caetano; Felipe Leite de Oliveira; Adriana Freitas Neves; Luiz Eurico Nasciutti; Luiz Ricardo Goulart; Etel Rodrigues Pereira Gimba
Journal:  BMC Cancer       Date:  2012-11-06       Impact factor: 4.430

10.  Cytogenetics and molecular genetics of myxoid soft-tissue sarcomas.

Authors:  Jun Nishio; Hiroshi Iwasaki; Kazuki Nabeshima; Masatoshi Naito
Journal:  Genet Res Int       Date:  2011-07-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.